Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole with cyclosporine A and mycophenolate for early post-allogeneic HSCT GVHD prophylaxis
ChiCTR2200059472Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of posaconazole in Hematopathy, invasive mycoses and graft-versus-host disease (GVHD), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Liver function, Renal function and 2 more. Started May 2022; status: recruiting.
02
Drugs
posaconazole
03
Conditions
Hematopathyinvasive mycosesgraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR2200059472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059472.